Skip to content

Author

N.S. Demirci

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Distinct renal adverse event profiles among CDK4/6 inhibitors: a comparative pharmacovigilance analysis

Objective Renal adverse events associated with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have gained increasing attention in clinical practice. However, comparative real-world data regarding renal safety profiles among individual CDK4/6 inhibitors remain limited. This study aimed to characterize renal adverse...

S. Guzel, A. M. Alan, Kubilay Tay et al. · 0 citations
Open access Sep 2026

Cetuximab-Related Skin Toxicity as a Prognostic Marker in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Analysis of the EXTREME Regimen

Cetuximab-induced skin toxicity was independently associated with improved OS in R/M HNSCC patients treated with the EXTREME regimen, suggesting its potential role as a pharmacodynamic biomarker of cetuximab efficacy.

M. Fidan, S. Safarov, H. Abbasov et al. · 0 citations
Open access Sep 2026

Association of PET/CT-Derived Metabolic Parameters with Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: An Analysis Across Molecular Subtypes

Background: Pathological complete response (pCR) following neoadjuvant systemic therapy (NST) is associated with improved outcomes in breast cancer. We evaluated the association between PET/CT-derived metabolic parameters and pCR and explored whether these associations differed according to molecular subtype. Methods:...

Z. Birsin, Mehmet Taner Bodur, S. Cebeci et al. · 0 citations
Open access Sep 2026

Progression Patterns as Determinants of Post-Progression Survival in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase 4/6 Inhibitors

In patients with HR+/HER2− metastatic breast cancer, the site of first progression after CDK4/6 inhibitor therapy may help estimate subsequent prognosis, and routinely available imaging findings may add practical value when assessing risk after CDK4/6 inhibitor failure.

Vali Aliyev, Z. Birsin, M. Günaltılı et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.